Harrow Secures Medicare Part D Access for Dry Eye Treatment Vevye

Harrow has announced that its dry eye disease treatment, Vevye, will be added to the formularies of key Medicare Part D plan sponsors starting January 1, 2025. Major plan sponsors including Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark, which collectively serve over 25 million Medicare Part D beneficiaries, will offer coverage for Vevye.

Expanding Access Beyond Medicare Part D

In addition to Medicare Part D, Vevye has secured broad insurance access across other healthcare programs. Harrow reports that the treatment is now covered by all U.S. Medicaid programs and approximately 60% of commercial insurance plans, ensuring that more patients have access to effective dry eye disease management.

“Medicare access is essential for Vevye's continued successful progression as a preferred dry eye disease prescription choice, and we’re thrilled to have secured these initial Medicare Part D formulary coverages—including with some of the largest 2025 Medicare Part D payers,” said Mark L. Baum, Chairman and CEO of Harrow. “For too long, Medicare beneficiaries have lacked an accessible, effective, and highly tolerable dry eye treatment. With 67 million Medicare beneficiaries in the U.S., including the 54 million with Medicare Part D prescription coverage, there is a substantial need for the unique clinical benefits that Vevye offers.”

Meeting the Needs of Medicare Beneficiaries with Dry Eye Disease

Harrow's expanded access to Vevye aims to address a significant need among seniors, who are at an increased risk for chronic dry eye disease, impacting their comfort, vision, and overall quality of life. “With this expanded access, we can better serve Medicare beneficiaries by improving their eye health, independence, and quality of life,” Baum added.

This expanded coverage for Vevye marks an important step forward in providing Medicare beneficiaries with a new, accessible option for managing dry eye disease effectively.